Philips and Paige have announced a strategic collaboration to deliver clinical-grade artificial intelligence (AI) applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify and characterise cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologist’s workflow and treatment planning for patients.
A press release reports that Paige’s technology has demonstrated promising results, and the collaboration aims to deliver this kind of technology into routine clinical practice. Several pathology laboratories have already converted their glass slide-based workflow to digital, using the clinically approved digital pathology solution from Philips. Once digital images are available, the CE marked Paige Prostate software has been designed to be automatically to detect and localise prostate cancer. This technology aims to provides pathologists with valuable information they can use in their evaluation of prostate biopsies.
Marlon Thompson, Business Leader of Digital & Computational Pathology at Philips, comments: “We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer. Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”
Leo Grady, CEO of Paige, says: “Pathology is transforming into a digital discipline and holds a strong promise for using AI solutions to aid, streamline, and enhance decision-making. Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients.”
Philips IntelliSite Pathology Solution in combination with Paige Prostate aims to provide an intuitive digital & computational pathology workflow experience. Philips plans to offer the CE-marked Paige Prostate to European pathology labs in 2020. AI solutions for other markets and additional disease areas are expected to follow suit.